NCT02195557已完成不适用
Synvisc® in Knee Osteoarthritis: Retrospective Follow-up in Treated Patients Since at Least Three Years
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 16
- 主要终点
- Time between two treatments
研究概览
简要总结
Retrospective collection of data, aimed at a better knowledge of the use of Synvisc® among the patients with knee osteoarthritis (OA) since at least three years.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients with knee osteoarthritis using Synvisc® since at least three years
排除标准
- 未提供
研究组 & 干预措施
Synvisc®
干预措施: Synvisc® (Drug)
结局指标
主要结局
Time between two treatments
时间窗: at least 3 years of observation
Reason for prescription
时间窗: at least 3 years before start of observation period
Number of other treatments per patient
时间窗: at least 3 years of observation
antalgics, non-steroid anti-inflammatory drugs (NSAIDs), steroid anti-inflammatory drugs (SAIDs), specific symptomatic treatments and surgery
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Retrospective Follow-up of Synvisc® in Active Patients With Knee OsteoarthritisOsteoarthritisNCT02195492Boehringer Ingelheim41
已完成
不适用
Use of Synvisc® in Knee Osteoarthritis - Survey on PracticeOsteoarthritisNCT02195544Boehringer Ingelheim70
已完成
不适用
Use of Synvisc® in Knee Osteoarthritis - Medico-economical StudyOsteoarthritisNCT02195505Boehringer Ingelheim374
已完成
3 期
A Study of the Safety and Efficacy of Synvisc in Patients With Symptomatic Shoulder OsteoarthritisMusculoskeletal DiseasesOsteoarthritisNCT00131300Genzyme, a Sanofi Company
已完成
3 期
A Study of the Safety and Efficacy of Synvisc in Patients With Symptomatic Ankle OsteoarthritisOsteoarthritisNCT00131768Genzyme, a Sanofi Company